source name	characteristics[organism]	characteristics[organism part]	characteristics[individual]	characteristics[cell type]	characteristics[ancestry category]	characteristics[age]	characteristics[sex]	characteristics[developmental stage]	characteristics[disease]	characteristics[depletion]	characteristics[sampling time]	assay name	Technology Type	comment[data file]	comment[file uri]	comment[fraction identifier]	comment[fractionation method]	comment[label]	comment[technical replicate]	comment[cleavage agent details]	comment[cleavage agent details]	comment[MS2 mass analyzer]	comment[instrument]	comment[separation]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[collision energy]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	factor value[sampling time]
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_1_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_1_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_1_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_1_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_1_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_1_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_1_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_1_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_1_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_1_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_1_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_1_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_1_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_1_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_1_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_1_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_1_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_1_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_1_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_1_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_1_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_1_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_1_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_1_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
1 plasma at -8 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_1_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
1 plasma at 0 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_1_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
1 plasma at 4 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_1_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
1 plasma at 13 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_1_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
1 plasma at 26 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_1_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
1 plasma at 39 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_1_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
1 plasma at 52 weeks	Homo sapiens	blood plasma	1	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_1_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_1_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_1_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_02_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_02_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_02_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_02_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_02_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_02_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_02_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_02_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_02_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_02_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_02_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_02_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_02_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_02_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_02_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_02_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_02_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_02_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_02_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_02_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_02_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_02_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_02_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_02_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
2 plasma at -8 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_02_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
2 plasma at 0 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_02_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
2 plasma at 4 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_02_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
2 plasma at 13 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_02_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
2 plasma at 26 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_02_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
2 plasma at 39 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_02_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
2 plasma at 52 weeks	Homo sapiens	blood plasma	2	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_02_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_02_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_02_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_03_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_03_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_03_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_03_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_03_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_03_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_03_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_03_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_03_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_03_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_03_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_03_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_03_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_03_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_03_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_03_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150824_qep1_lc7_phge_sa_plate4d_03_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_03_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_03_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_03_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_03_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_03_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_03_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_03_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
3 plasma at -8 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_03_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
3 plasma at 0 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_03_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
3 plasma at 4 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_03_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
3 plasma at 13 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_03_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
3 plasma at 26 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_03_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
3 plasma at 39 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_03_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
3 plasma at 52 weeks	Homo sapiens	blood plasma	3	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_03_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_03_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_03_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_05_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_05_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_05_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_05_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_05_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_05_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_05_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_05_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_05_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_05_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_05_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_05_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_05_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_05_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_05_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_05_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_05_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_05_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_05_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_05_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_05_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 4 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_05_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
5 plasma at 13 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_05_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_05_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_05_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 52 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_05_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_05_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_05_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
5 plasma at -8 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_05_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate3b_05_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
5 plasma at 26 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate3b_05_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_05_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_05_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
5 plasma at 39 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate3c_05_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_05_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_05_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
5 plasma at 0 weeks	Homo sapiens	blood plasma	5	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc8_phge_sa_plate3d_05_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate3D_05_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate3D_05_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_06_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_06_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_06_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_06_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_06_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_06_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_06_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_06_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_06_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_06_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_06_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_06_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_06_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_06_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_06_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_06_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_06_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_06_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_06_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_06_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_06_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_06_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_06_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at -8 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_06_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_06_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
6 plasma at 4 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_06_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
6 plasma at 13 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_06_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
6 plasma at 26 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_06_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
6 plasma at 39 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_06_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
6 plasma at 52 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_06_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_06_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_06_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
6 plasma at 0 weeks	Homo sapiens	blood plasma	6	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate2c_06_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2C_06_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2C_06_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_07_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_07_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_07_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_07_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_07_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_07_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_07_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_07_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_07_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_07_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_07_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_07_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_07_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_07_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_07_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_07_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_07_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_07_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_07_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_07_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_07_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_07_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_07_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at -8 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_07_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
7 plasma at 0 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_07_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_07_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
7 plasma at 13 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_07_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
7 plasma at 26 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_07_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
7 plasma at 39 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_07_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
7 plasma at 52 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_07_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_07_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_07_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
7 plasma at 4 weeks	Homo sapiens	blood plasma	7	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate1d_07_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate1D_07_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate1D_07_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_08_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_08_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_08_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_08_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_08_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_08_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_08_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_08_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_08_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_08_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_08_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_08_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_08_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_08_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_08_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_08_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_08_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_08_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_08_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_08_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_08_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_08_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_08_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_08_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
8 plasma at -8 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_08_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
8 plasma at 0 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_08_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
8 plasma at 4 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_08_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
8 plasma at 13 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_08_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
8 plasma at 26 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_08_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
8 plasma at 39 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_08_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
8 plasma at 52 weeks	Homo sapiens	blood plasma	8	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_08_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_08_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_08_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_09_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_09_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_09_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_09_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_09_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_09_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_09_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_09_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_09_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_09_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_09_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_09_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_09_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_09_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_09_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_09_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150824_qep1_lc7_phge_sa_plate4d_09_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_09_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_09_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_09_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_09_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_09_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_09_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_09_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
9 plasma at -8 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_09_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
9 plasma at 0 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_09_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
9 plasma at 4 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_09_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
9 plasma at 13 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_09_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
9 plasma at 26 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_09_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
9 plasma at 39 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_09_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
9 plasma at 52 weeks	Homo sapiens	blood plasma	9	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_09_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_09_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_09_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_10_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_10_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_10_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_10_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_10_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_10_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_10_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_10_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_10_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_10_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_10_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_10_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_10_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_10_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_10_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_10_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_10_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_10_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_10_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_10_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_10_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_10_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_10_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 0 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_10_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
10 plasma at 4 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_10_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
10 plasma at 13 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_10_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
10 plasma at 26 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_10_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
10 plasma at 39 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_10_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_10_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_10_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
10 plasma at -8 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_10_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_10_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
10 plasma at 52 weeks	Homo sapiens	blood plasma	10	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate3b_10_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_10_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_10_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_11_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_11_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_11_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_11_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_11_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_11_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_11_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_11_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_11_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_11_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_11_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_11_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_11_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_11_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_11_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_11_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_11_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_11_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_11_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_11_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_11_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_11_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_11_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_11_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
11 plasma at -8 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_11_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
11 plasma at 0 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_11_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
11 plasma at 4 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_11_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
11 plasma at 13 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_11_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
11 plasma at 26 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_11_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
11 plasma at 39 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_11_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
11 plasma at 52 weeks	Homo sapiens	blood plasma	11	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_11_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_11_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_11_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_12_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_12_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_12_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_12_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_12_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_12_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_12_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_12_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_12_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_12_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_12_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_12_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_12_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_12_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_12_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_12_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_12_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_12_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_12_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_12_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_12_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_12_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_12_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at -8 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_12_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
12 plasma at 0 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_12_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_12_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
12 plasma at 13 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_12_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
12 plasma at 26 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_12_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
12 plasma at 39 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_12_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
12 plasma at 52 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_12_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_12_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_12_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
12 plasma at 4 weeks	Homo sapiens	blood plasma	12	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate2a_12_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_12_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_14_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_14_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_14_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_14_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_14_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_14_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_14_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_14_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_14_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_14_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_14_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_14_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_14_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_14_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_14_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_14_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150824_qep1_lc7_phge_sa_plate4d_14_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_14_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_14_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_14_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_14_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_14_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_14_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_14_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
14 plasma at -8 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_14_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
14 plasma at 0 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_14_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
14 plasma at 4 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_14_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
14 plasma at 13 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_14_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
14 plasma at 26 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_14_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
14 plasma at 39 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_14_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
14 plasma at 52 weeks	Homo sapiens	blood plasma	14	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_14_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_14_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_14_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_15_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_15_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_15_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_15_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_15_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_15_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_15_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_15_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_15_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_15_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_15_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_15_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_15_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_15_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_15_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_15_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_15_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_15_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_15_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_15_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_15_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_15_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_15_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at -8 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_15_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
15 plasma at 0 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_15_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
15 plasma at 4 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_15_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
15 plasma at 13 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_15_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
15 plasma at 26 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_15_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
15 plasma at 39 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_15_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_15_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_15_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
15 plasma at 52 weeks	Homo sapiens	blood plasma	15	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate3b_15_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_15_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_15_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_16_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_16_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_16_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_16_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_16_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_16_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_16_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_16_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_16_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_16_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_16_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_16_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_16_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_16_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_16_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_16_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_16_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_16_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_16_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_16_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_16_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_16_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_16_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_16_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
16 plasma at 0 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_16_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
16 plasma at 4 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_16_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
16 plasma at 13 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_16_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
16 plasma at 26 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_16_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
16 plasma at 39 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_16_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
16 plasma at 52 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_16_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_16_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_16_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
16 plasma at -8 weeks	Homo sapiens	blood plasma	16	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4d_16_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4D_16_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4D_16_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_17_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_17_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_17_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_17_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_17_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_17_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_17_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_17_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_17_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_17_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_17_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_17_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_17_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_17_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_17_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_17_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_17_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_17_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_17_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_17_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_17_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_17_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_17_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_17_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
17 plasma at -8 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_17_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
17 plasma at 0 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_17_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
17 plasma at 4 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_17_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
17 plasma at 13 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_17_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
17 plasma at 26 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_17_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
17 plasma at 39 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_17_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
17 plasma at 52 weeks	Homo sapiens	blood plasma	17	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_17_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_17_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_17_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_19_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_19_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_19_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_19_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_19_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_19_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_19_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_19_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_19_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_19_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_19_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_19_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_19_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_19_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_19_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_19_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_19_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_19_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_19_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_19_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_19_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_19_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_19_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_19_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
19 plasma at -8 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_19_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
19 plasma at 0 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_19_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
19 plasma at 4 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_19_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
19 plasma at 13 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_19_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
19 plasma at 26 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_19_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
19 plasma at 39 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_19_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
19 plasma at 52 weeks	Homo sapiens	blood plasma	19	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_19_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_19_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_19_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_20_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_20_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_20_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_20_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_20_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_20_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_20_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_20_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_20_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_20_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_20_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_20_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_20_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_20_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_20_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_20_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_20_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_20_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_20_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_20_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_20_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_20_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_20_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_20_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
20 plasma at -8 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_20_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
20 plasma at 0 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_20_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
20 plasma at 4 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_20_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
20 plasma at 13 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_20_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
20 plasma at 26 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_20_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
20 plasma at 39 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_20_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
20 plasma at 52 weeks	Homo sapiens	blood plasma	20	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_20_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_20_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_20_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_21_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_21_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_21_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_21_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_21_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_21_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_21_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_21_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_21_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_21_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_21_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_21_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_21_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_21_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_21_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_21_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_21_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_21_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_21_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_21_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_21_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_21_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_21_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_21_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
21 plasma at -8 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_21_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
21 plasma at 0 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_21_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
21 plasma at 4 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_21_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
21 plasma at 13 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_21_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
21 plasma at 26 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_21_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
21 plasma at 39 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_21_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
21 plasma at 52 weeks	Homo sapiens	blood plasma	21	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_21_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_21_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_21_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_22_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_22_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_22_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_22_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_22_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_22_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_22_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_22_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_22_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_22_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_22_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_22_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_22_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_22_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_22_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_22_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_22_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_22_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_22_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_22_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_22_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_22_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_22_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_22_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
22 plasma at -8 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_22_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
22 plasma at 0 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_22_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
22 plasma at 4 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_22_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
22 plasma at 13 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_22_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
22 plasma at 26 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_22_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
22 plasma at 39 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_22_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
22 plasma at 52 weeks	Homo sapiens	blood plasma	22	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_22_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_22_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_22_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_23_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_23_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_23_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_23_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_23_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_23_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_23_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_23_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_23_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_23_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_23_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_23_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_23_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_23_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_23_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_23_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_23_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_23_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_23_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_23_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_23_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_23_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 0 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_23_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
23 plasma at 4 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_23_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_23_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 26 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_23_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_23_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
23 plasma at 52 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_23_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_23_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_23_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
23 plasma at -8 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_23_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
23 plasma at 13 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate3b_23_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
23 plasma at 39 weeks	Homo sapiens	blood plasma	23	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate3b_23_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_23_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_23_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_24_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_24_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_24_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_24_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_24_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_24_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_24_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_24_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_24_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_24_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_24_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_24_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
24 plasma at -8 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_24_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_24_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_24_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
24 plasma at 0 weeks	Homo sapiens	blood plasma	24	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_24_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_24_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_24_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_25_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_25_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_25_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_25_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_25_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_25_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_25_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_25_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_25_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_25_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_25_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_25_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_25_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_25_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_25_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_25_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_25_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_25_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_25_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_25_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_25_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_25_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_25_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 0 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_25_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
25 plasma at 4 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_25_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_25_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
25 plasma at 26 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_25_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
25 plasma at 39 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_25_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
25 plasma at 52 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_25_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_25_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_25_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
25 plasma at -8 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate2a_25_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_25_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_25_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
25 plasma at 13 weeks	Homo sapiens	blood plasma	25	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate2a_25_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate2A_25_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate2A_25_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_26_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_26_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_26_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_26_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_26_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_26_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_26_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_26_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_26_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_26_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_26_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_26_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_26_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_26_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_26_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_26_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_26_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_26_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_26_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_26_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_26_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_26_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at -8 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_26_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
26 plasma at 0 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_26_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
26 plasma at 4 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_26_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
26 plasma at 13 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_26_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_26_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 39 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_26_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
26 plasma at 52 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_26_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_26_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_26_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate3a_26_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3A_26_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3A_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
26 plasma at 26 weeks	Homo sapiens	blood plasma	26	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate3b_26_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_26_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_26_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_27_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_27_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_27_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_27_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_27_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_27_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_27_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_27_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_27_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_27_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_27_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_27_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_27_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_27_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_27_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_27_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_27_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_27_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_27_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_27_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_27_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_27_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_27_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_27_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
27 plasma at -8 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_27_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
27 plasma at 0 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_27_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
27 plasma at 4 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_27_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
27 plasma at 13 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_27_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
27 plasma at 26 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_27_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
27 plasma at 39 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_27_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
27 plasma at 52 weeks	Homo sapiens	blood plasma	27	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_27_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_27_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_27_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_28_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_28_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_28_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_28_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_28_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_28_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_28_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_28_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_28_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_28_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_28_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_28_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_28_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_28_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_28_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_28_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_28_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_28_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_28_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_28_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_28_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_28_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_28_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at -8 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_28_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
28 plasma at 0 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_28_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
28 plasma at 4 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_28_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
28 plasma at 13 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_28_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_28_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
28 plasma at 39 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_28_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
28 plasma at 52 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_28_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_28_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_28_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
28 plasma at 26 weeks	Homo sapiens	blood plasma	28	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc8_phge_sa_plate1c_28_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate1C_28_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate1C_28_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_29_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_29_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_29_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_29_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_29_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_29_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_29_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_29_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_29_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_29_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_29_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_29_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_29_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_29_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_29_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_29_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_29_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_29_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_29_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_29_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_29_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_29_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_29_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_29_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
29 plasma at -8 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_29_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
29 plasma at 0 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_29_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
29 plasma at 4 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_29_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
29 plasma at 13 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_29_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
29 plasma at 26 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_29_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
29 plasma at 39 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_29_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
29 plasma at 52 weeks	Homo sapiens	blood plasma	29	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_29_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_29_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_29_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_30_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_30_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_30_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_30_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_30_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_30_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_30_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_30_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_30_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_30_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_30_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_30_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_30_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_30_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_30_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_30_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_30_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_30_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_30_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_30_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_30_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_30_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_30_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_30_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
30 plasma at -8 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_30_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
30 plasma at 0 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_30_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
30 plasma at 4 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_30_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
30 plasma at 13 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_30_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
30 plasma at 26 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_30_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
30 plasma at 39 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_30_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
30 plasma at 52 weeks	Homo sapiens	blood plasma	30	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_30_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_30_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_30_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_31_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_31_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_31_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_31_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_31_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_31_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_31_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_31_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_31_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_31_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_31_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_31_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
31 plasma at -8 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_31_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_31_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_31_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
31 plasma at 0 weeks	Homo sapiens	blood plasma	31	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_31_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_31_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_31_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_33_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_33_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_33_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_33_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_33_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_33_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_33_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_33_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_33_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_33_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_33_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_33_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at -8 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3c_33_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_33_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_33_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
33 plasma at 0 weeks	Homo sapiens	blood plasma	33	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate3d_33_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3D_33_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3D_33_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_34_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_34_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_34_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_34_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_34_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_34_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_34_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_34_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_34_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_34_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_34_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_34_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_34_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_34_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_34_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_34_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_34_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_34_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_34_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_34_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_34_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at -8 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_34_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
34 plasma at 0 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_34_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_34_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_34_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 26 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_34_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_34_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
34 plasma at 52 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_34_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_34_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_34_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
34 plasma at 4 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate3b_34_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
34 plasma at 13 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate3b_34_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
34 plasma at 39 weeks	Homo sapiens	blood plasma	34	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate3b_34_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_34_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_34_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_35_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_35_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_35_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_35_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_35_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_35_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_35_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_35_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_35_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_35_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_35_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_35_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
35 plasma at 0 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_35_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_35_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_35_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
35 plasma at -8 weeks	Homo sapiens	blood plasma	35	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_35_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_35_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_35_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_36_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_36_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_36_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_36_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_36_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_36_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_36_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_36_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_36_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_36_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_36_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_36_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_36_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_36_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_36_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_36_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_36_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_36_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_36_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_36_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_36_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_36_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_36_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_36_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
36 plasma at -8 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_36_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
36 plasma at 0 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_36_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
36 plasma at 4 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_36_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
36 plasma at 13 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_36_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
36 plasma at 26 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_36_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
36 plasma at 39 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_36_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
36 plasma at 52 weeks	Homo sapiens	blood plasma	36	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_36_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_36_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_36_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_37_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_37_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_37_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_37_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_37_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_37_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_37_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_37_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_37_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_37_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_37_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_37_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_37_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_37_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_37_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_37_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_37_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_37_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_37_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_37_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_37_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_37_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_37_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at -8 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_37_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
37 plasma at 0 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_37_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
37 plasma at 4 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_37_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
37 plasma at 13 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_37_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
37 plasma at 26 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_37_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_37_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
37 plasma at 52 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_37_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_37_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_37_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
37 plasma at 39 weeks	Homo sapiens	blood plasma	37	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate3c_37_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3C_37_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3C_37_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_38_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_38_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_38_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_38_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_38_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_38_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_38_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_38_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_38_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_38_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_38_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_38_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_38_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_38_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_38_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_38_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_38_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_38_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_38_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_38_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_38_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_38_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_38_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_38_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
38 plasma at -8 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_38_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
38 plasma at 0 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_38_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
38 plasma at 4 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_38_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
38 plasma at 13 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_38_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
38 plasma at 26 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_38_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
38 plasma at 39 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_38_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
38 plasma at 52 weeks	Homo sapiens	blood plasma	38	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_38_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_38_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_38_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_39_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_39_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_39_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_39_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_39_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_39_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_39_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_39_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_39_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_39_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_39_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_39_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_39_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_39_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_39_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_39_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_39_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_39_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_39_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_39_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_39_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_39_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_39_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_39_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 0 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_39_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
39 plasma at 4 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_39_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
39 plasma at 26 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_39_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
39 plasma at 39 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_39_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
39 plasma at 52 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_39_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_39_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_39_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
39 plasma at -8 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_39_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_39_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_39_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
39 plasma at 13 weeks	Homo sapiens	blood plasma	39	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate3d_39_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3D_39_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3D_39_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_40_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_40_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_40_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_40_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_40_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_40_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_40_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_40_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_40_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_40_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_40_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_40_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_40_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_40_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_40_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_40_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_40_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_40_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_40_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_40_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_40_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_40_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_40_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_40_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
40 plasma at -8 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_40_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
40 plasma at 0 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_40_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
40 plasma at 4 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_40_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
40 plasma at 13 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_40_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
40 plasma at 26 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_40_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
40 plasma at 39 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_40_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
40 plasma at 52 weeks	Homo sapiens	blood plasma	40	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_40_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_40_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_40_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_41_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_41_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_41_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_41_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_41_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_41_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_41_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_41_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_41_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_41_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_41_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_41_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_41_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_41_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_41_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_41_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_41_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_41_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_41_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_41_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_41_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_41_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_41_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_41_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
41 plasma at -8 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_41_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
41 plasma at 0 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_41_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
41 plasma at 4 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_41_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
41 plasma at 13 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_41_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
41 plasma at 26 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_41_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
41 plasma at 39 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_41_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
41 plasma at 52 weeks	Homo sapiens	blood plasma	41	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_41_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_41_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_41_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_42_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_42_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_42_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_42_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_42_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_42_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_42_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_42_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_42_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_42_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_42_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_42_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_42_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_42_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_42_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_42_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_42_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_42_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_42_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_42_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_42_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_42_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at -8 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_42_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
42 plasma at 0 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_42_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
42 plasma at 4 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_42_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
42 plasma at 13 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_42_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_42_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 39 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_42_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
42 plasma at 52 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_42_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_42_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_42_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc8_phge_sa_plate2a_42_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate2A_42_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate2A_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
42 plasma at 26 weeks	Homo sapiens	blood plasma	42	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc8_phge_sa_plate2b_42_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate2B_42_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate2B_42_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_43_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_43_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_43_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_43_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_43_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_43_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_43_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_43_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_43_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_43_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_43_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_43_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_43_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_43_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_43_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_43_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150824_qep1_lc7_phge_sa_plate4d_43_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_43_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_43_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_43_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_43_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_43_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_43_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_43_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
43 plasma at -8 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_43_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
43 plasma at 0 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_43_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
43 plasma at 4 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_43_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
43 plasma at 13 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_43_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
43 plasma at 26 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_43_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
43 plasma at 39 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_43_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
43 plasma at 52 weeks	Homo sapiens	blood plasma	43	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_43_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_43_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_43_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_44_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_44_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_44_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_44_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_44_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_44_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_44_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_44_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_44_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_44_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_44_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_44_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_44_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_44_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_44_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_44_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_44_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_44_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_44_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_44_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_44_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
44 plasma at 4 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_44_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
44 plasma at 13 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_44_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
44 plasma at 26 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_44_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
44 plasma at 39 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_44_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
44 plasma at 52 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_44_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_44_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_44_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
44 plasma at 0 weeks	Homo sapiens	blood plasma	44	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc8_phge_sa_plate1c_44_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate1C_44_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate1C_44_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_45_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_45_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_45_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_45_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_45_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_45_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_45_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_45_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_45_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_45_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_45_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_45_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_45_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_45_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_45_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_45_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_45_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_45_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_45_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_45_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_45_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_45_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_45_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_45_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
45 plasma at -8 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_45_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
45 plasma at 0 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_45_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
45 plasma at 4 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_45_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
45 plasma at 13 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_45_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
45 plasma at 26 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_45_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
45 plasma at 39 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_45_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
45 plasma at 52 weeks	Homo sapiens	blood plasma	45	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_45_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_45_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_45_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_46_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_46_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_46_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_46_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_46_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_46_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_46_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_46_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_46_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_46_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_46_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_46_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_46_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_46_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_46_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_46_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_46_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_46_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_46_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_46_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_46_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_46_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_46_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 0 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_46_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
46 plasma at 4 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_46_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
46 plasma at 13 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_46_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
46 plasma at 26 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_46_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_46_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
46 plasma at 52 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_46_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_46_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_46_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
46 plasma at -8 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate3b_46_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_46_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_46_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
46 plasma at 39 weeks	Homo sapiens	blood plasma	46	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate3b_46_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_46_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_46_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_47_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_47_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_47_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_47_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_47_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_47_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_47_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_47_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_47_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_47_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_47_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_47_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_47_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_47_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_47_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_47_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_47_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_47_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_47_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_47_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_47_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_47_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_47_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_47_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
47 plasma at -8 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_47_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
47 plasma at 0 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_47_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
47 plasma at 4 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_47_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
47 plasma at 13 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_47_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
47 plasma at 26 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_47_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
47 plasma at 39 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_47_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
47 plasma at 52 weeks	Homo sapiens	blood plasma	47	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_47_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_47_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_47_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_48_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_48_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150701_qep1_lc7_phge_sa_plate3a_48_3	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150701_qep1_lc7_phge_sa_plate3a_48_4	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150701_qep1_lc7_phge_sa_plate3a_48_5	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150701_qep1_lc7_phge_sa_plate3a_48_6	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150701_qep1_lc7_phge_sa_plate3a_48_7	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_48_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_48_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150725_qep1_lc7_phge_sa_plate3b_48_3	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150725_qep1_lc7_phge_sa_plate3b_48_4	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150725_qep1_lc7_phge_sa_plate3b_48_5	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150725_qep1_lc7_phge_sa_plate3b_48_6	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150725_qep1_lc7_phge_sa_plate3b_48_7	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_48_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_48_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_48_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150818_qep1_lc7_phge_sa_plate3c_48_3	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150818_qep1_lc7_phge_sa_plate3c_48_4	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150818_qep1_lc7_phge_sa_plate3c_48_5	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150818_qep1_lc7_phge_sa_plate3c_48_6	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150818_qep1_lc7_phge_sa_plate3c_48_7	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_48_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at -8 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_48_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_48_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
48 plasma at 4 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150912_qep1_lc7_phge_sa_plate3d_48_3	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
48 plasma at 13 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150912_qep1_lc7_phge_sa_plate3d_48_4	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
48 plasma at 26 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150912_qep1_lc7_phge_sa_plate3d_48_5	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
48 plasma at 39 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150912_qep1_lc7_phge_sa_plate3d_48_6	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
48 plasma at 52 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150912_qep1_lc7_phge_sa_plate3d_48_7	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_48_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_48_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
48 plasma at 0 weeks	Homo sapiens	blood plasma	48	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate3b_48_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate3B_48_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate3B_48_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_49_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_49_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_49_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_49_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_49_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_49_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_49_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_49_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_49_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_49_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_49_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_49_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
49 plasma at -8 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_49_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_49_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_49_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
49 plasma at 0 weeks	Homo sapiens	blood plasma	49	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_49_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_49_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_49_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_50_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_50_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_50_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_50_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_50_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_50_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_50_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_50_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_50_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_50_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_50_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_50_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
50 plasma at -8 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_50_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_50_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_50_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
50 plasma at 0 weeks	Homo sapiens	blood plasma	50	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_50_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_50_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_50_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_51_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_51_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_51_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_51_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_51_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_51_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_51_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_51_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_51_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_51_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_51_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_51_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
51 plasma at -8 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_51_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_51_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_51_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
51 plasma at 0 weeks	Homo sapiens	blood plasma	51	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc8_phge_sa_plate3d_51_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_Plate3D_51_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_Plate3D_51_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150624_qep1_lc7_phge_sa_plate2a_52_1	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150624_qep1_lc7_phge_sa_plate2a_52_2	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150624_qep1_lc7_phge_sa_plate2a_52_3	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150624_qep1_lc7_phge_sa_plate2a_52_4	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150624_qep1_lc7_phge_sa_plate2a_52_5	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150624_qep1_lc7_phge_sa_plate2a_52_6	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150624_qep1_lc7_phge_sa_plate2a_52_7	proteomic profiling by mass spectrometry	20150624_QEp1_LC7_PhGe_SA_Plate2A_52_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150624_QEp1_LC7_PhGe_SA_Plate2A_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150811_qep1_lc7_phge_sa_plate2b_52_1	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150811_qep1_lc7_phge_sa_plate2b_52_2	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150811_qep1_lc7_phge_sa_plate2b_52_3	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150811_qep1_lc7_phge_sa_plate2b_52_4	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150811_qep1_lc7_phge_sa_plate2b_52_5	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150811_qep1_lc7_phge_sa_plate2b_52_6	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150811_qep1_lc7_phge_sa_plate2b_52_7	proteomic profiling by mass spectrometry	20150811_QEp1_LC7_PhGe_SA_Plate2B_52_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150811_QEp1_LC7_PhGe_SA_Plate2B_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150827_qep1_lc7_phge_sa_plate2c_52_1	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150827_qep1_lc7_phge_sa_plate2c_52_2	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150827_qep1_lc7_phge_sa_plate2c_52_3	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150827_qep1_lc7_phge_sa_plate2c_52_4	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150827_qep1_lc7_phge_sa_plate2c_52_5	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150827_qep1_lc7_phge_sa_plate2c_52_6	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150827_qep1_lc7_phge_sa_plate2c_52_7	proteomic profiling by mass spectrometry	20150827_QEp1_LC7_PhGe_SA_Plate2C_52_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150827_QEp1_LC7_PhGe_SA_Plate2C_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
52 plasma at -8 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150907_qep1_lc7_phge_sa_plate2d_52_1	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
52 plasma at 0 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150907_qep1_lc7_phge_sa_plate2d_52_2	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
52 plasma at 4 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150907_qep1_lc7_phge_sa_plate2d_52_3	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
52 plasma at 13 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150907_qep1_lc7_phge_sa_plate2d_52_4	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
52 plasma at 26 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150907_qep1_lc7_phge_sa_plate2d_52_5	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
52 plasma at 39 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150907_qep1_lc7_phge_sa_plate2d_52_6	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
52 plasma at 52 weeks	Homo sapiens	blood plasma	52	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150907_qep1_lc7_phge_sa_plate2d_52_7	proteomic profiling by mass spectrometry	20150907_QEp1_LC7_PhGe_SA_Plate2D_52_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150907_QEp1_LC7_PhGe_SA_Plate2D_52_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_53_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_53_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_53_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_53_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_53_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_53_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_53_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_53_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_53_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_53_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_53_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_53_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
53 plasma at -8 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_53_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_53_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_53_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
53 plasma at 0 weeks	Homo sapiens	blood plasma	53	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_53_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_53_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_53_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150701_qep1_lc7_phge_sa_plate3a_54_1	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_54_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150701_qep1_lc7_phge_sa_plate3a_54_2	proteomic profiling by mass spectrometry	20150701_QEp1_LC7_PhGe_SA_Plate3A_54_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150701_QEp1_LC7_PhGe_SA_Plate3A_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150725_qep1_lc7_phge_sa_plate3b_54_1	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_54_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150725_qep1_lc7_phge_sa_plate3b_54_2	proteomic profiling by mass spectrometry	20150725_QEp1_LC7_PhGe_SA_Plate3B_54_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150725_QEp1_LC7_PhGe_SA_Plate3B_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150818_qep1_lc7_phge_sa_plate3c_54_1	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_54_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150818_qep1_lc7_phge_sa_plate3c_54_2	proteomic profiling by mass spectrometry	20150818_QEp1_LC7_PhGe_SA_Plate3C_54_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150818_QEp1_LC7_PhGe_SA_Plate3C_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
54 plasma at -8 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150912_qep1_lc7_phge_sa_plate3d_54_1	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_54_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_54_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
54 plasma at 0 weeks	Homo sapiens	blood plasma	54	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150912_qep1_lc7_phge_sa_plate3d_54_2	proteomic profiling by mass spectrometry	20150912_QEp1_LC7_PhGe_SA_Plate3D_54_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150912_QEp1_LC7_PhGe_SA_Plate3D_54_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150618_qep1_lc7_phge_sa_plate1b_57_1	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150618_qep1_lc7_phge_sa_plate1b_57_2	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150618_qep1_lc7_phge_sa_plate1b_57_3	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150618_qep1_lc7_phge_sa_plate1b_57_4	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150618_qep1_lc7_phge_sa_plate1b_57_5	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150618_qep1_lc7_phge_sa_plate1b_57_6	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150618_qep1_lc7_phge_sa_plate1b_57_7	proteomic profiling by mass spectrometry	20150618_QEp1_LC7_PhGe_SA_Plate1B_57_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150618_QEp1_LC7_PhGe_SA_Plate1B_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150708_qep1_lc7_phge_sa_plate1c_57_1	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150708_qep1_lc7_phge_sa_plate1c_57_2	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150708_qep1_lc7_phge_sa_plate1c_57_3	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150708_qep1_lc7_phge_sa_plate1c_57_4	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150708_qep1_lc7_phge_sa_plate1c_57_5	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150708_qep1_lc7_phge_sa_plate1c_57_6	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150708_qep1_lc7_phge_sa_plate1c_57_7	proteomic profiling by mass spectrometry	20150708_QEp1_LC7_PhGe_SA_Plate1C_57_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150708_QEp1_LC7_PhGe_SA_Plate1C_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150805_qep1_lc7_phge_sa_plate1d_57_1	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150805_qep1_lc7_phge_sa_plate1d_57_2	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150805_qep1_lc7_phge_sa_plate1d_57_3	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150805_qep1_lc7_phge_sa_plate1d_57_4	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150805_qep1_lc7_phge_sa_plate1d_57_5	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150805_qep1_lc7_phge_sa_plate1d_57_6	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150805_qep1_lc7_phge_sa_plate1d_57_7	proteomic profiling by mass spectrometry	20150805_QEp1_LC7_PhGe_SA_Plate1D_57_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150805_QEp1_LC7_PhGe_SA_Plate1D_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
57 plasma at -8 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150901_qep1_lc7_phge_sa_plate1e_57_1	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
57 plasma at 0 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150901_qep1_lc7_phge_sa_plate1e_57_2	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
57 plasma at 4 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150901_qep1_lc7_phge_sa_plate1e_57_3	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
57 plasma at 13 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150901_qep1_lc7_phge_sa_plate1e_57_4	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
57 plasma at 26 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150901_qep1_lc7_phge_sa_plate1e_57_5	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
57 plasma at 39 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150901_qep1_lc7_phge_sa_plate1e_57_6	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
57 plasma at 52 weeks	Homo sapiens	blood plasma	57	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150901_qep1_lc7_phge_sa_plate1e_57_7	proteomic profiling by mass spectrometry	20150901_QEp1_LC7_PhGe_SA_Plate1E_57_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150901_QEp1_LC7_PhGe_SA_Plate1E_57_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4b_58_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4b_58_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4b_58_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4b_58_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4b_58_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4b_58_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4b_58_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4B_58_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4B_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150731_qep1_lc7_phge_sa_plate4e_58_1	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150731_qep1_lc7_phge_sa_plate4e_58_2	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150731_qep1_lc7_phge_sa_plate4e_58_3	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150731_qep1_lc7_phge_sa_plate4e_58_4	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150731_qep1_lc7_phge_sa_plate4e_58_5	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150731_qep1_lc7_phge_sa_plate4e_58_6	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150731_qep1_lc7_phge_sa_plate4e_58_7	proteomic profiling by mass spectrometry	20150731_QEp1_LC7_PhGe_SA_Plate4E_58_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150731_QEp1_LC7_PhGe_SA_Plate4E_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150824_qep1_lc7_phge_sa_plate4d_58_1	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150824_qep1_lc7_phge_sa_plate4d_58_2	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150824_qep1_lc7_phge_sa_plate4d_58_3	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150824_qep1_lc7_phge_sa_plate4d_58_4	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150824_qep1_lc7_phge_sa_plate4d_58_5	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150824_qep1_lc7_phge_sa_plate4d_58_6	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150824_qep1_lc7_phge_sa_plate4d_58_7	proteomic profiling by mass spectrometry	20150824_QEp1_LC7_PhGe_SA_Plate4D_58_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150824_QEp1_LC7_PhGe_SA_Plate4D_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
58 plasma at -8 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	-8W	20150917_qep1_lc7_phge_sa_plate4c_58_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	-8W
58 plasma at 0 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	0W	20150917_qep1_lc7_phge_sa_plate4c_58_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	0W
58 plasma at 4 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	4W	20150917_qep1_lc7_phge_sa_plate4c_58_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	4W
58 plasma at 13 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	13W	20150917_qep1_lc7_phge_sa_plate4c_58_4	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_4.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	13W
58 plasma at 26 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	26W	20150917_qep1_lc7_phge_sa_plate4c_58_5	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_5.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_5.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	26W
58 plasma at 39 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	39W	20150917_qep1_lc7_phge_sa_plate4c_58_6	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_6.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_6.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	39W
58 plasma at 52 weeks	Homo sapiens	blood plasma	58	not applicable	not available	not available	not available	not available	obesity	no depletion	52W	20150917_qep1_lc7_phge_sa_plate4c_58_7	proteomic profiling by mass spectrometry	20150917_QEp1_LC7_PhGe_SA_Plate4C_58_7.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC7_PhGe_SA_Plate4C_58_7.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	4	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	52W
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F1 plasma at not applicable weeks	Homo sapiens	blood plasma	F1	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f1_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F2 plasma at not applicable weeks	Homo sapiens	blood plasma	F2	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f2_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F2_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
F3 plasma at not applicable weeks	Homo sapiens	blood plasma	F3	not applicable	not available	not available	female	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_f3_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_F3_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M1 plasma at not applicable weeks	Homo sapiens	blood plasma	M1	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m1_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M1_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M2 plasma at not applicable weeks	Homo sapiens	blood plasma	M2	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m2_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M2_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_1	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_1.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	1	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_2	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_2.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	2	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
M3 plasma at not applicable weeks	Homo sapiens	blood plasma	M3	not applicable	not available	not available	male	not available	uninfected	depleted fraction	not applicable	20150917_qep1_lc8_phge_sa_doubletop14_m3_3	proteomic profiling by mass spectrometry	20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2016/12/PXD004242/20150917_QEp1_LC8_PhGe_SA_DoubleTop14_M3_3.raw	1	no fractionation	AC=MS:1002038;NT=label free sample	3	NT=Trypsin; AC=MS:1001251; CS=(?<=[KR])(?!P)	NT=Lys-C; AC=MS:1001309; CS='(?<=K)(?\!P)'	AC=MS:1000484; NT=Orbitrap	AC=MS:1002523; NT=Q Exactive HF	AC=PRIDE:0000563;NT=Reversed-phase chromatography	NT=Carbamidomethyl;AC=UNIMOD:4;TA=C;MT=Fixed	NT=Oxidation;AC=UNIMOD:35;MT=Variable;TA=M	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	AC=MS:1000422;NT=HCD	27 NCE	7 ppm	20 ppm	not applicable
